Summary: The aim of this study was to evaluate maternal plasma total fibronectin values in pregnancy-associated hypertension in women in the third trimester of pregnancy. A total of 125 pregnant women at the 24th week of gestation participated in this study. Nonpregnant normotensive women were included as control group (n = 30). Plasma samples for fibronectin were obtained at the 24th, 28th, and 32nd weeks of gestation from all pregnant patients. From this cohort, 10 patients met the criteria for the diagnosis of gestational hypertension and 15 women met the stringent requirements of preeclampsia, whereas 100 patients were normotensive later in gestation. Plasma total fibronectin levels were determined by radial immunodiffusion technique. Data were analyzed using the SPSS program. The mean plasma fibronectin levels of the pregnant women in whom gestational hypertension and preeclampsia developed were significantly higher at the 24th, 28th, and 32nd weeks in comparison to normotensive pregnant women (p < 0.001). However, throughout the period from the 24th to 32nd weeks of pregnancy, plasma total fibronectin levels did not exhibit a significant change in normotensive pregnant patients or in patients with preeclampsia and gestational hypertension. There was also no correlation between plasma fibronectin levels and gestational age, mean arterial pressure, birth weight, and 5-minute Apgar scores in all groups (p < 0.05). The elevated maternal plasma fibronectin level over 40 mg/dL is capable of predicting preeclampsia with a sensitivity of 73% and a specificity of 92%. These results suggest that serial plasma fibronectin measurements before 24 weeks' of gestation may be helpful in the early detection of preeclampsia in normotensive gravid women who are destined to become clinically preeclamptic. Key Words: Fibronectin-Preeclampsia-Gestational hypertension-Turkish population.
of preeclamptic women (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) . Furthermore, others have reported that an increment in fibronectin levels in serial plasma measurements could be used as a valuable marker for the prediction of preeclampsia (15) (16) (17) .
The aim of this study was to evaluate the predictive value of serial plasma fibronectin concentrations in women with pregnancy-associated hypertension in the Turkish population where preeclampsia-eclampsia is still a major cause of perinatal mortality and morbidity.
MATERIALS AND METHODS
This study included 145 pregnant women at 24 weeks' gestation, admitted to the antenatal clinic of Trakya University, School of Medicine between October 1999 and December 2000. The study was approved by the Institutional Review Board and all patients gave verbal informed consent. These pregnant women were asked to participate in this prospective study of gestational hypertension at their antenatal visits. Exclusion criteria were age younger than 18 years; diabetes mellitus; chronic hypertension; connective tissue disorders; multiple pregnancies; or renal, cardiovascular, or trophoblastic diseases. Patients who had an operation within the last 12 months or received any type of blood products during their pregnancy were also excluded from the study. From this cohort of 145 patients, eight women were excluded because of development of gestational diabetes or renal disease during their pregnancy and 12 women were lost during the study, which left a total of 125 pregnant women in our study.
The diagnosis of preeclampsia, gestational hypertension, and chronic hypertension was done according to the criteria agreed by the National High Blood Pressure Education Program Working Group of National Institutes of Health (NIH) in 2000 (18) . The blood pressure was measured with a calibrated aneroid manometer in the supine position after a 5-minute rest. The diastolic pressure value was determined according to the Korotkoff phase IV. Mean arterial pressure (MAP) was measured by the suggested formula (19) : [systolic blood pressure + (2 × diastolic blood pressure)]/3. Gestational hypertension was defined as blood pressure greater than or equal to 140/90 mmHg during the second half of pregnancy or an increase of 30 mmHg systolic and/or 15 mmHg diastolic blood pressure, compared with the values obtained at the first prenatal visit and manifested at least twice, greater than or equal to 6 hours apart (20) . Preeclampsia was defined as gestational hypertension with the presence of proteinuria greater than 300 mg/24 hours and edema greater than 1+ after bed rest (18) . From our cohort of 125 pregnant patients, ten patients met the criteria for the diagnosis of gestational hypertension, whereas 15 pregnant women met the stringent requirements of preeclampsia later in gestation. The remaining 100 pregnant women were normotensive. An additional 30 nonpregnant normotensive women were included as control group. These women were healthy volunteers randomly selected from the health workers in our hospital and were matched to the study patients by age.
Plasma samples for fibronectin were initially obtained at the 24th week of pregnancy from all patients. Thereafter, following plasma samples were drawn at the 28th and the 32nd weeks to obtain a plasma fibronectin profile by venipuncture from a peripheral vein. The blood samples (4.5 mL) were collected into a sterile tube containing 0.5 mL sodium citrate after an overnight fast between 8:00 AM and 9:00 AM. Plateletpoor plasma was prepared by centrifugation at 3000 rev/min for 20 minutes. To avoid interassay and intraassay variation, samples for plasma fibronectin examinations were collected and stored at -70ºC until assayed and were measured in the same assay. Total plasma fibronectin was determined by radial immunodiffusion technique using a commercial assay kit (LC Partigen-Dade, Behring, Marburg, Germany). Values between 2.5 and 40 mg/dL were considered normal, as suggested by the manufacturers'. Maternal plasma fibronectin levels have been used as the predictor of endothelial damage in preeclampsia. The alteration in plasma fibronectin levels from the 24th to 28th and 32nd weeks of gestation were taken into consideration to detect preeclampsia before its onset. Furthermore, we searched the relationship between plasma fibronectin levels and the severity of disease.
Data were stored and analyzed with the SPSS program (Statistical Package for Social Science, release 9.0; SPSS, Chicago, IL) for Windows. All results were expressed as mean ± SD. Data with normal distribution were analyzed with student t test and Kruskal-Wallis U-test was performed for the non-parametric parameters that were not normally distributed. Categoric variables were analyzed with the chi-square test when sample size was adequate and with Fisher exact test otherwise. Also, Pearson correlation analysis was used for linear correlations. A p value less than 0.05 was considered statistically significant.
RESULTS
Patient characteristics are shown in Table 1 . Age and parity were similar in all groups. As expected, MAP values in patients with gestational hypertension and preeclampsia were significantly higher than the values in the controls and normotensive pregnant women (p > 0.05). However, these values were similar in normotensive controls and normotensive pregnant patients or in patients with gestational hypertension and preeclampsia (p < 0.05).
In comparison to normotensive pregnant women, the mean ± SD plasma fibronectin levels of the pregnant women with gestational hypertension and women in whom preeclampsia developed were significantly higher at the 24th, 28th, and 32nd weeks (p < 0.001) ( Table 2) . We also investigated correlations between gestational age, MAP, birth weight, 5-minute Apgar scores, and plasma fibronectin levels in all groups. There was no correlation between plasma fibronectin levels and these parameters (p < 0.05).
In a further analysis, we investigated the effect of serial fibronectin levels on the prediction of preeclampsia. However, throughout the period from the 24th to 32nd weeks of pregnancy, plasma total fibronectin levels did not exhibit a statistically significant change in normotensive pregnant patients or in patients with preeclampsia and gestational hypertension (Fig. 1) .
The median (min.-max.) gestational week for patients in whom preeclampsia developed was 30 (26-36) weeks. As shown in Table 3 , 11 of 15 patients with preeclampsia exhibited fibronectin values over the upper limit of 40 mg/dL, whereas only eight of 100 normotensive pregnant women had high fibronectin levels over that particular limit. The elevated maternal plasma fibronectin level over 40 mg/dL is capable of predicting preeclampsia, with a sensitivity of 73% and a specificity of 92%. The positive and the negative predictive values were 62% and 72%, respectively. On the other hand, the false positive rate was 8% and the false-negative rate was 27%.
In another analysis, we evaluated the fibronectin values of the normotensive pregnant women at the 24th, 28th, and 32nd weeks of gestation and calculated the mean ± SD fibronectin value, which was 27.3 ± 2.4 mg/dL. The mean ± SD plasma fibronectin level in normotensive pregnant women was similar to that in the normotensive nonpregnant controls (27.3 ± 2.4 vs. 29.94 ± 4.30 mg/dL, p > 0.05).
DISCUSSION
We found significantly elevated plasma total fibronectin levels in pregnant women who developed gestational hypertension and preeclampsia compared to normotensive pregnant women at the 24th, 28th, and 32nd weeks of pregnancy. However, plasma total fibronectin levels did not significantly change throughout the period from 24 to 32 weeks of gestation in patients in whom preeclampsia or gestational hypertension developed.
Early recognition of the risk of preeclampsia in pregnant women improves pregnancy outcome via careful monitorization and preventive treatment. Therefore, screening tests for preeclampsia are important to identify the patient at risk. Plasma total fibronectin concentrations have been used as a screening test for early recognition of preeclampsia (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (15) (16) (17) . Maternal vascular endothelial damage plays a critical role in the development of preeclampsia (16) . Because plasma fibronectin is a marker of endothelial damage (5, 21) , total or cellular fibronectin determinations have been used to differentiate normal and preeclamptic pregnancies (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) . In our study, we evaluated ED-B fibronectin, an isoform of fibronectin, which is synthesized in the endothelium of blood vessels and released to the extracellular space at sites of vascular injury. In line with other studies (6,7,13,22-24), we found elevated plasma total fibronectin levels in women in whom preeclampsia developed compared to healthy pregnant counterparts. Besides, women in whom gestational hypertension developed exhibited elevated plasma fibronectin levels compared to levels in healthy pregnant women.
Trend analysis of plasma total fibronectin levels during pregnancy has been found to be helpful for the early prediction of the development of true preeclampsia in healthy and initially normotensive pregnant women (11, 16) . However, the data on trend analysis and the initiation time of the increase in plasma fibronectin levels in women who are destined to develop preeclampsia in the course of pregnancy are inconclusive. A significant increment in fibronectin levels during the second half of gestation in women with preeclampsia has been observed in some studies, as in our study (5, 15, 25) . Besides, Paarlberg and associates (12) and Sud and colleagues (17) have even asserted that pregnant women in whom preeclampsia developed later on have first trimester elevations in serum total fibronectin levels before clinical signs of preeclampsia become apparent. On the contrary, several authors demonstrated this increasing tendency in fibronectin started in the third trimester of gestation (10) . However, the authors have concluded that longitudinal assessment of plasma fibronectin levels has poor clinical predictive capacity and would not be a useful predictor for screening of preeclampsia in low-risk pregnant women (10, 12) . In our study, plasma samples were initially collected at the 24th gestational week, so we could not show a time-dependent increase in fibronectin concentrations in women in whom preeclampsia or gestational hypertension developed. The lack of an increasing trend in fibronectin concentrations in our study is somehow surprising, but may be explained by the hypothesis that fibronectin levels had already increased before the 24th week and thus did not increase thereafter.
It has been proposed that preeclampsia is characterized by an exaggerated systemic inflammatory response that is expected in normal pregnancy (4) . Normal pregnancy itself stimulates an inflammatory response. However, in preeclampsia, these changes becomes excessive and a more generalized immune response occurs, involving all cellular elements of intravascular inflammatory responses rather than the endothelium alone (4) . Because maternal inflammatory responses may be variable and normal pregnancy and preeclampsia may be part of the same continuum, these may offer another explanation for the similar trend in fibronectin levels in healthy pregnant women and women with preeclampsia.
Some authors have found that fibronectin levels do not change throughout normal gestation (5, 12, 26, 27) . We also did not observe a significant increment in plasma fibronectin levels from the 24th to 32nd weeks of gestation in normotensive pregnant women. Besides, there was no difference in fibronectin between healthy pregnant and nonpregnant women in our study. On the other hand, some authors agreed that fibronectin levels increased as pregnancy advanced (7, 10) . The lack of an increasing trend in fibronectin concentrations in normal pregnant women or a difference between pregnant and nonpregnant women may show that endothelial damage does not occur in normal pregnancy. Another possible explanation may be that although an endothelial damage occurs in normal pregnancy, this would not reflect a systemic response or demonstrate a clinical effect on systemic vasculature.
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Our study prospectively analyzed a total of three plasma samples from each participant at the 24th, 28th, and 32nd weeks. For the prediction of preeclampsia, while some investigators evaluated fibronectin longitudinally monthly starting from the first trimester of pregnancy (15) , other studies (12,13) tested plasma samples obtained in the first, second, and the third trimesters of gestation. Lockwood and Peters (16) evaluated only single plasma samples at varying gestational ages. The time interval between blood samplings in our study corresponds to the standard period for antenatal visits for low-risk patients. However, this interval can be adjusted in high-risk pregnant patients. All 125 patients who participated to our study were all randomly selected low-risk pregnancies, and high-risk pregnancies were excluded from the study.
Another point of concern was the methods performed for fibronectin determination in different studies. Nephelometric (6, 8, 12, 22) , turbidimetric (10), and enzyme-linked immunosorbent assay (ELISA) (17) methods have been used for fibronectin measurement. Brubaker and colleagues (26) compared all three methods for the evaluation of plasma fibronectin in preeclamptic and healthy pregnant women. They found that turbidimetric method and ELISA were less effective for distinguishing normal pregnant and preeclamptic women, whereas nephelometric method seemed more effective in the third trimester of pregnancy. Chavarria and associates (15) also performed specific enzyme immunoassay method. Our study used radial immunodiffusion method, which was rather sensitive in differentiating preeclampsia from normal pregnant women.
Plasma fibronectin levels over the upper limit of 40 mg/dL, indicate a preeclampsia risk with a sensitivity of 73% and a specificity of 92%. Akgül and associates (28) prospectively observed 30 pregnant women, seven who developed preeclampsia. They found that the sensitivity and specificity values for elevated plasma fibronectin levels were 100% and 96%, respectively. However, the positive predictive value was high (86%) compared to the value we obtained (62%). Moreover, Chavarria and associates (15) calculated 3.8 µg/mL as the cutoff value for fibronectin for the early prediction of preeclampsia. In their study, sensitivity, specificity, and positive and negative predictive values were 73%, 87%, 29%, and 98%, respectively.
We found no correlation between birth weight and plasma fibronectin levels in all groups. However, some authors observed a negative correlation between birth weight and plasma fibronectin levels in preeclamptic women and they explained this correlation by the diminished utero-placental flow in the placental bed in preeclampsia (9, 29) .
In conclusion, plasma total fibronectin levels were elevated in pregnant women in whom gestational hypertension and preeclampsia developed compared to normotensive pregnant women in the third trimester of gestation. Because of the already confirmed increase in fibronectin concentrations at the 24th week, plasma fibronectins may be investigated before this week in normotensive gravid women for the prediction of preeclampsia.
